Compare VIAV & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIAV | BIO |
|---|---|---|
| Founded | 1923 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.3B |
| IPO Year | 1996 | 1994 |
| Metric | VIAV | BIO |
|---|---|---|
| Price | $30.87 | $366.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | $56.00 | ★ $356.67 |
| AVG Volume (30 Days) | ★ 6.5M | 234.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | 0.29 | ★ 11.25 |
| Revenue | $1,518,300,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $34.44 | N/A |
| Revenue Next Year | $14.47 | $1.86 |
| P/E Ratio | $112.17 | ★ $32.84 |
| Revenue Growth | ★ 40.03 | 0.65 |
| 52 Week Low | $15.51 | $236.73 |
| 52 Week High | $60.43 | $396.23 |
| Indicator | VIAV | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 45.98 |
| Support Level | $25.73 | $354.27 |
| Resistance Level | $36.85 | $391.44 |
| Average True Range (ATR) | 2.45 | 13.26 |
| MACD | 0.39 | -0.39 |
| Stochastic Oscillator | 64.07 | 35.93 |
Viavi Solutions Inc is a world-wide leader in test and measurement and optical technologies. Its test and measurement, and resilient Position, Navigation and Timing (PNT) solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, it develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets. The company's segments are Network and Service Enablement (NSE); and Optical Security and Performance Products (OSP). Majority of revenue comes from NSE segment. It has presence in Americas, Asia-Pacific, and EMEA. Majority of revenue is from America.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.